Navigation Links
Abbott Offers Aluvia to Thailand in Return for Compulsory Licensing Halt

Abbott Laboratories said this week that it is willing to proceed with the registration of a heat stable version of lopinavir/ritonavir called Aluvia in Thailand if the Thai// government will halt its plans for a compulsory license to allow imports of a generic version from India, and will sell it to the Thai government for $1000 a year.

Abbott has been in dispute with the Thai government since January 2007, when plans for a compulsory license to import lopinavir/ritonavir were first announced by the Thais. Abbott retaliated by withdrawing seven products from drug registration processes in Thailand, including Aluvia.

In February Abbott offered a price cut to $167 a month for Kaletra, the soft-gel capsule version of lopinavir/ritonavir.

Earlier in April Abbott announced that it was cutting the price of Kaletra and Aluvia when registered to $1000 a year in 40 lower middle-income countries following discussions with World Health Organization director-general Margaret Chan. But the company said that its offer would only apply where its patents are respected, a clear warning to the Thai government.

According to the Wall Street Journal, Abbott chief executive Miles White said that the decision to withdraw Aluvia from registration had been driven by “concern that compulsory licensing would be abused ever-more widely, using HIV as an excuse."

But last month Abbott public affairs staff insisted that the company’s action was not related to HIV drugs, but to a lack of respect for `numerous` patents.

Treatment advocates have urged the Thai government not to back down on its compulsory licensing policy.

“The fact that Thailand has been brave enough to issue a compulsory license means that 40 countries are now able to get Kaletra for $1000 a year,” said Paul Cawthorne, head of mission for Médecins sans Frontières in Thailand, speaking during a phone briefing for journalists earlier today.
The Thai government says that negotiations will continue.

A version of lopinavir/ritonavir alleged to be heat-stable was recently launched by the Indian company Emcure. However no data is available on the manufacturer’s website to explain the stablility of Emletra, and the product has not been prequalified by the World Health Organization.

Source-Generef.com'"/>




Related medicine news :

1. Pharmacia may take 51.5 percent Abbott stake
2. Abbott Laboratories to buy Biocompatibles cardiovascular stent business
3. Abbott’s Laboratories R&D Capabilities Questione
4. Abbott Receives CE Mark Certification
5. Abbott to Subsidize Price of HIV Drug
6. Pancreatitis: Minimially Invasive Procedure Offers Long-Term Pain Relief
7. Drug Offers Hope for Alzheimers disease
8. Drug Firm Offers to Donate Smallpox Vaccine
9. fMRI Offers Insight Into An Infants Brain
10. Gel Offers A More Targeted Approach
11. Umbilical Cord Blood Offers Hope For Patients Who Require Bone Marrow Transplants
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/26/2017)... ... April 26, 2017 , ... ... is proud to announce that it has received 510(k) clearance from the U.S. ... Home and the MyoCycle Pro. , Both devices are stationary cycling systems that ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... an agreement to be the preferred physical therapy provider for Derby City CrossFit, ... to Derby City CrossFit as quickly and effectively as possible, ProRehab’s sports physical ...
(Date:4/25/2017)... ... April 25, 2017 , ... As ... decision-makers are preparing for how his administration could impact the employee benefits industry. ... what changes are most likely to make it through Congress. His discussion will ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... Lake Park ... smiles by using Invisalign® in Lutz, FL. With the help of this ... and aesthetics with fewer potential complications, more discretion and less pain. , Drs. ...
(Date:4/25/2017)... ... April 25, 2017 , ... As Spring reignites vigilance ... research related to Zika virus during pregnancy, as well as other prenatal exposures ... science. , The Teratology Society is an international and multidisciplinary ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), a ... significant unmet medical needs, today announced that it ... product development program, based on its proprietary self-delivering ... Dermatology (SID) 76 th Annual Meeting.  The ... sciences relevant to skin health and disease through ...
(Date:4/20/2017)... 2017 Research and Markets has announced ... Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive ... offering. ... market was valued at US$ 7,167.6 Mn in 2015, and ... at a CAGR of 5.6% from 2016 to 2024. ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 Cardiology ... during the projected period The Cardiology Devices segment ... more than US$ 15 Mn in 2018 over 2017. By ... reach a market valuation close to US$ 700 Mn, expanding ... Cardiology Devices segment dominated the Asia Pacific ...
Breaking Medicine Technology: